Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer H Böger

Showing results (1-10 of 174) with videos related to

Pageof 18
Sort By:
The Journal of Nutrition|October 7, 2004
Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factorRainer H Böger
Alternative Therapies in Health and Medicine|April 24, 2014
The pharmacodynamics of L-arginineRainer H Böger
Critical Care (London, England)|November 11, 2006
Live and let die: asymmetric dimethylarginine and septic shockRainer H Böger
The Journal of Nutrition|May 22, 2007
The pharmacodynamics of L-arginineRainer H Böger
Annals of Medicine|April 4, 2006
Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyondRainer H Böger
European Heart Journal|October 31, 2003
When the endothelium cannot say 'NO' anymore. ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular diseaseRainer H Böger
Vascular Medicine (London, England)|February 1, 2006
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trialsRainer H Böger
Current Opinion in Clinical Nutrition and Metabolic Care|December 20, 2007
L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous?Rainer H Böger
Cardiovascular Research|October 14, 2003
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factorRainer H Böger
Clinical Chemistry and Laboratory Medicine|December 6, 2003
Association of asymmetric dimethylarginine and endothelial dysfunctionRainer H Böger
Pageof 18

Showing results (1-10 of 174) with videos related to

Sort By:
Pageof 18
The Journal of Nutrition|October 7, 2004
Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factorRainer H Böger
Alternative Therapies in Health and Medicine|April 24, 2014
The pharmacodynamics of L-arginineRainer H Böger
Critical Care (London, England)|November 11, 2006
Live and let die: asymmetric dimethylarginine and septic shockRainer H Böger
The Journal of Nutrition|May 22, 2007
The pharmacodynamics of L-arginineRainer H Böger
Annals of Medicine|April 4, 2006
Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyondRainer H Böger
European Heart Journal|October 31, 2003
When the endothelium cannot say 'NO' anymore. ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular diseaseRainer H Böger
Vascular Medicine (London, England)|February 1, 2006
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trialsRainer H Böger
Current Opinion in Clinical Nutrition and Metabolic Care|December 20, 2007
L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous?Rainer H Böger
Cardiovascular Research|October 14, 2003
The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factorRainer H Böger
Clinical Chemistry and Laboratory Medicine|December 6, 2003
Association of asymmetric dimethylarginine and endothelial dysfunctionRainer H Böger
Pageof 18